MIR1271

Summary

MIR1271 (microRNA 1271, HGNC:35252) is a microRNA gene on chromosome 5q35.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302203 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35252
Approved symbol	MIR1271
Name	microRNA 1271
Location	5q35.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-1271
Ensembl gene	ENSG00000221464
Ensembl biotype	miRNA
Entrez	100302203
RNAcentral	URS000075C9F1 — miRNA, 86 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000408537

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000408537 — 1 exons

Exon	Start	End
ENSE00001565172	176367946	176368031

Expression profiles

Bgee: expression breadth broad, 83 present calls, max score 81.58.

Top tissues by expression

83 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	81.58	gold quality
vermiform appendix	UBERON:0001154	79.58	gold quality
blood	UBERON:0000178	78.09	gold quality
adult mammalian kidney	UBERON:0000082	76.52	gold quality
fundus of stomach	UBERON:0001160	75.83	gold quality
right lobe of thyroid gland	UBERON:0001119	75.65	gold quality
kidney	UBERON:0002113	75.16	gold quality
muscle of leg	UBERON:0001383	74.68	gold quality
bone marrow	UBERON:0002371	73.55	gold quality
gastrocnemius	UBERON:0001388	73.36	gold quality
monocyte	CL:0000576	73.30	gold quality
islet of Langerhans	UBERON:0000006	72.77	gold quality
calcaneal tendon	UBERON:0003701	71.70	gold quality
minor salivary gland	UBERON:0001830	71.07	gold quality
heart	UBERON:0000948	71.04	gold quality
heart left ventricle	UBERON:0002084	70.77	gold quality
left adrenal gland cortex	UBERON:0035825	70.68	gold quality
endometrium	UBERON:0001295	70.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	70.23	gold quality
stomach	UBERON:0000945	69.93	gold quality
urinary bladder	UBERON:0001255	69.63	gold quality
tibial artery	UBERON:0007610	69.36	gold quality
myometrium	UBERON:0001296	69.29	gold quality
lung	UBERON:0002048	69.25	gold quality
right lobe of liver	UBERON:0001114	69.20	gold quality
left coronary artery	UBERON:0001626	69.06	gold quality
right atrium auricular region	UBERON:0006631	68.86	gold quality
body of pancreas	UBERON:0001150	68.62	gold quality
body of stomach	UBERON:0001161	68.43	gold quality
lower esophagus	UBERON:0013473	67.84	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.31

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• In a subgroup of hepatocellular carcinoma, the up-regulation of glypican-3 was associated with a concomitant down-regulation of its repressor miR-1271. (PMID:22865282)
• The miR-1271 could regulate cisplatin resistance in human gastric cancer cells, at least partially, via targeting the IGF1R/IRS1 pathway. (PMID:24875127)
• MiR-1271 inhibits cell proliferation, invasion, and epithelial-mesenchymal transition in gastric cancer by directly suppressing FOXQ1 expression. (PMID:26159618)
• miR-1271 may have a role in promoting growth in ovarian cancer (PMID:26477861)
• expression of ZEB1 and TWIST1, which are master regulators of tumor metastasis. Our study first indicates that miR-1271 functions as a suppressor in regulating of pancreatic cancer EMT by targeting ZEB1 and TWIST1. (PMID:26940738)
• Findings suggest that the induction of microRNA miR-1271 by saturated fatty acid palmitate promotes the development of insulin resistance by targeting insulin receptor (INSR) and insulin receptor substrate 1 protein (IRS-1) in hepatocytes. (PMID:27613089)
• Expression of miR-1271 is downregulated in multiple myeloma.MiR-1271 functions as a tumor suppressor that inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting SMO-mediated HH signaling pathway. (PMID:27959416)
• Taken together, our results suggest that DIXDC1 plays an important role in regulating prostate cancer cell proliferation and invasion. Targeting DIXDC1 by miR-1271 may be a promising therapeutic strategy for prostate cancer. (PMID:28153722)
• Results suggest that miR-1271 may regulate the expression of Foxk2 in non-small cell lung cancer. (PMID:28260088)
• FOXK2, regulted by miR-1271-5p, promotes cell growth and indicates unfavorable prognosis in hepatocellular carcinoma (PMID:28506857)
• miR1271 inhibited glioma cell growth by targeting FN1, and a low level of miR1271 in glioma tumor tissues was associated with lower survival rates in patients with glioma. (PMID:28535003)
• Our results suggested that reduced expression of miR-1271 may be involved in the ERG expression and that miR-1271 could be a therapeutic target for ERG-positive prostate cancer patients (PMID:28551819)
• MiR-1271 was significantly downregulated in human endometrial cancer tissues. (PMID:28682437)
• Data suggest that MIR1271 is down-regulated in colorectal cancer tissues and cell lines; MIR1271 appears to negatively regulate MTDH expression in colorectal cancer cells; MIR1271 also activates Wnt signaling and suppresses proliferation and invasion/movement of colorectal cancer cells. (MIR1271 = microRNA-1271; MTDH = metadherin) (PMID:29315995)
• Capn4 and miR-1271 may serve as potential therapeutic targets for the treatment of colorectal cancer. (PMID:29331762)
• MiR-1271 inhibits hepatocellular carcinoma metastasis and epithelial-mesenchymal transition by targeting the PTP4A1/c-Src signaling pathway.PTP4A1 is a direct downstream target of miR-1271. (PMID:29345291)
• MiR-1271 is a potent tumor suppressor in pancreatic cancer, its pro-apoptotic function was partially mediated by reduced AKT/MTOR signaling (PMID:29461595)
• miR-1271 can suppress breast cancer cell proliferation and progression by targeting SPIN1 expression. (PMID:29771421)
• The chemo-resistance of GBM cells may be promoted after suppressing miR-1271 through cell survival mediated with Bcl-2. (PMID:30248541)
• MiR12715p inhibited the progression of AML by targeting ZIC2. (PMID:30483794)
• Our data uncover the ERalpha-miR-1271-SNAI2 feedback loop and provide a mechanism to explain the TGF-beta network in breast cancer progression. (PMID:30823890)
• Long non-coding RNA TTN-AS1 aggravates carcinogenesis through Wnt/beta-catenin signaling pathway by sponging miR-1271 in hepatocellular carcinoma. (PMID:31295985)
• MiR-1271 inhibits cell proliferation and metastasis by targeting LDHA in endometrial cancer. (PMID:31298316)
• Downregulation of lncRNA UCA1 facilitates apoptosis and reduces proliferation in multiple myeloma via regulation of the miR-1271-5p/HGF axis. (PMID:31356563)
• MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway. (PMID:31599424)
• The long non-coding RNA HCG18 promotes the growth and invasion of colorectal cancer cells through sponging miR-1271 and upregulating MTDH/Wnt/beta-catenin. (PMID:31854468)
• MicroRNA-1271-5p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma. (PMID:32275316)
• Characterising the Transcriptional and Translational Impact of the Schizophrenia-Associated miR-1271-5p in Neuronal Cells. (PMID:32325711)
• microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ERbeta. (PMID:32448371)
• Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2. (PMID:32515146)
• Circular RNA circMBOAT2 promotes prostate cancer progression via a miR-1271-5p/mTOR axis. (PMID:32645691)
• Long noncoding RNA AC092171.4 promotes hepatocellular carcinoma progression by sponging microRNA-1271 and upregulating GRB2. (PMID:32692718)
• Effects of circRNA_103993 on the proliferation and apoptosis of NSCLC cells through miR-1271/ERG signaling pathway. (PMID:32894545)
• RP11619L19.2 promotes colon cancer development by regulating the miR12715p/CD164 axis. (PMID:33125110)
• Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. (PMID:33277569)
• MiRNA-1271-5p regulates osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by targeting forkhead box O1 (FOXO1). (PMID:33675274)
• MicroRNA12715p alleviates the malignant development of hepatitis B virusmediated liver cancer via binding to AQP5. (PMID:33760167)
• Circular RNA ABCB10 promotes cell proliferation and invasion, but inhibits apoptosis via regulating the microRNA1271mediated Capn4/Wnt/betacatenin signaling pathway in epithelial ovarian cancer. (PMID:33760208)
• Molecular Mechanisms of miR-1271 Dysregulation in Human Cancer. (PMID:34015233)
• M2 macrophage-derived exosomes carry miR-1271-5p to alleviate cardiac injury in acute myocardial infarction through down-regulating SOX6. (PMID:34058620)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.